Microcrystalline chitosan is ineffective to decrease plasma lipids in both apolipoprotein E ε4 carriers and non-carriers: A long-term placebo-controlled trial in hypercholesterolaemic volunteers

Basic and Clinical Pharmacology and Toxicology

Volumn 97, Issue 2, 2005, Pages 98-103

  Lehtimäki, Terho ^a   Metso, Saara ^a   Ylitalo, Ritva ^b   Rontu, Riikka ^a   Nikkilä, Matti ^c   Wuolijoki, Erkki ^a,d   Ylitalo, Pauli ^a,b  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c Tampere City Hospital   (Finland)

^d Finn Medi Research Ltd   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; CHITOSAN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; ALLELE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CRYSTAL; DOUBLE BLIND PROCEDURE; FEMALE; GENOTYPE; GLUCOSE BLOOD LEVEL; HETEROZYGOTE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; ANTILIPEMIC AGENTS; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BLOOD GLUCOSE; CHITOSAN; CHOLESTEROL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HETEROZYGOTE; HUMANS; HYPERCHOLESTEROLEMIA; LIPIDS; MALE; MIDDLE AGED;

EID: 22544457477     PISSN: 17427835     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2005.pto_111.x     Document Type: Article

References (23)

1. Angelin, B., L. Holmquist, B. Leijd & K. Einarsson: Bile acid metabolism in familial dysbetalipoproteinaemia: studies in subjects with the apolipoprotein E-2/2 phenotype. Eur. J. Clin. Invest. 1990, 20, 143-149.
2. Brenninkmeijer, B. J., P. M. Stuyt, P. N. Demacker, A. F. Stalenhoef & A. Van't Laar: Catabolism of chylomicron remnants in normolipidemic subjects in relation to the apoprotein E phenotype. J. Lipid Res. 1987, 28, 361-370.
3. Friedewald, W. T., R. I. Levy & D. S. Fredrickson: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972, 18, 499-502.
4. Gallaher, D. D., C. M. Gallaher, G. J. Mahrt, T. P. Carr, C. H. Hollingshead, R. Hesslink, Jr. & J. Wise: A glucomannan and chitosan fiber supplement decreases plasma cholesterol and increases cholesterol excretion in overweight normocholesterolemic humans. J. Amer. Coll. Nutr. 2002, 21, 428-433.
5. Gylling, H., K. Kontula & T. A. Miettinen: Cholesterol absorption and metabolism and LDL kinetics in healthy men with different apolipoprotein E phenotypes and apolipoprotein B Xba I and LDL receptor Pvu II genotypes. Arterioscler. Thromb. Vasc. Biol. 1995, 15, 208-213.
6. Ho, S. C., E. S. Tai, P. H. Eng, C. E. Tan & A. C. Fok: In the absence of dietary surveillance, chitosan does not reduce plasma lipids or obesity in hypercholesterolaemic obese Asian subjects. Singapore Med. J. 2001, 42, 6-10.
7. Jing, S. B., L. Li, D. Ji, Y. Takiguchi & T. Yamaguchi: Effect of chitosan on renal function in patients with chronic renal failure. J. Pharm. Pharmacol. 1997, 49, 721-723.
8. Kesäniemi, Y. A., C. Ehnholm & T. A. Miettinen: Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype. J. Clin. Invest. 1987, 80, 578-581.
9. Koch, W., A. Ehrenhaft, K. Griesser, A. Pfeufer, J. Muller, A. Schomig & A. Kastrati: TaqMan systems for genotyping of disease-related polymorphisms present in the gene encoding apolipoprotein E. Clin. Chem. Lab. Med 2002, 40, 1123-1231.
10. Lala, A., A. Scoppola, C. Motti, C. Cortese, D. Caccese & G. Menzinger: Apolipoprotein E genotype and cholesterogenesis in polygenic hypercholesterolemia. Metabolism 1998, 47, 97-100.
11. Lehtimäki, T., T. Moilanen, T. Solakivi, P. Laippala, & C. Ehnholm: Cholesterol-rich diet induced changes in plasma lipids in relation to apolipoprotein E phenotype in healthy students. Ann. Med. 1992, 24, 61-66.
12. Livak, K. J.: Allelic discrimination using fluorogenic probes and the 5′-nuclease assay. Genet. Anal. 1999, 14, 143-149.
13. Maitland-van der Zee, A. H., O. H. Klungel, B. H. Stricker, W. M. Monique Verschuren, J. J. Kastelein, H. G. Leufkens & A. de Boer: Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors. Atherosclerosis 2002, 163, 213-222.
14. Metso, S., R. Ylitalo, M. Nikkilä, E. Wuolijoki, P. Ylitalo & T. Lehtimäki: The effect of long-term microcrystalline chitosan therapy on plasma lipids and glucose concentrations in subjects with increased plasma total cholesterol: a randomised placebo-controlled double-blind crossover trial in healthy men and women. Eur. J. Clin. Pharmacol. 2003, 59, 741-746.
15. Miettinen, T. A.: Impact of apo E phenotype on the regulation of cholesterol metabolism. Ann. Med. 1991, 23, 181-186.
16. Miettinen, T. A., H. Gylling & H. Vanhanen: Serum cholesterol response to dietary cholesterol and apoprotein E phenotype. Lancet 1988, 2, 1261.
17. Mooser, V., D. M. Waterworth, T. Isenhour & L. Middleton: Cardiovascular pharmacogenetics in the SNP era. J. Thromb. Haemost. 2003, 1, 1398-1402.
18. Mänttäri, M., P. Koskinen, C. Ehnholm, J. K. Huttunen & V. Manninen: Apolipoprotein E polymorphism influences the serum cholesterol response to dietary intervention. Metabolism 1991, 40, 217-221.
19. Pittler, M. H., N. C. Abbot, E. F. Harkness, & E. F. Ernst: Randomized, double-blind trial of chitosan for body weight reduction. Eur. J. Clin. Nutr. 1999, 53, 379-381.
20. Tikkanen, M. J., J. K, Huttunen, C. Ehnholm & P. Pietinen: Apolipoprotein E4 homozygosity predisposes to serum cholesterol elevation during high fat diet. Arteriosclerosis 1990, 10, 285-288.
21. Weintraub, M. S., S. Eisenberg & J. L. Breslow: Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E. J. Clin. Invest. 1987, 80, 1571-1577.
22. Wuolijoki, E., T. Hirvelä & P. Ylitalo: Decrease in serum LDL cholesterol with microcrystalline chitosan. Meth. Find Exp. Clin. Pharmacol. 1999, 21, 357-361.
23. Ylitalo, R., S. Lehtinen, E. Wuolijoki, P. Ylitalo & T. Lehtimäki: Cholesterol-lowering properties and safety of chitosan. Arzneimittelforsch. 2002, 52, 1-7.